118 related articles for article (PubMed ID: 34034308)
21. Radiation Dosimetry in
Jackson PA; Hofman MS; Hicks RJ; Scalzo M; Violet J
J Nucl Med; 2020 Jul; 61(7):1030-1036. PubMed ID: 31806772
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic schemes in 177Lu and 90Y-PRRT: radiobiological considerations.
Sarnelli A; Guerriero F; Botta F; Ferrari M; Strigari L; Bodei L; D'Errico V; Grassi E; Fioroni F; Paganelli G; Orecchia R; Cremonesi M
Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):216-231. PubMed ID: 26576734
[TBL] [Abstract][Full Text] [Related]
23. Three-dimensional Monte Carlo-based voxel-wise tumor dosimetry in patients with neuroendocrine tumors who underwent
Goetz TI; Lang EW; Prante O; Maier A; Cordes M; Kuwert T; Ritt P; Schmidkonz C
Ann Nucl Med; 2020 Apr; 34(4):244-253. PubMed ID: 32114682
[TBL] [Abstract][Full Text] [Related]
24. Side Effects of CXC-Chemokine Receptor 4-Directed Endoradiotherapy with Pentixather Before Hematopoietic Stem Cell Transplantation.
Maurer S; Herhaus P; Lippenmeyer R; Hänscheid H; Kircher M; Schirbel A; Maurer HC; Buck AK; Wester HJ; Einsele H; Grigoleit GU; Keller U; Lapa C
J Nucl Med; 2019 Oct; 60(10):1399-1405. PubMed ID: 30850502
[TBL] [Abstract][Full Text] [Related]
25. Cholecystokinin 2 Receptor Agonist
Rottenburger C; Nicolas GP; McDougall L; Kaul F; Cachovan M; Vija AH; Schibli R; Geistlich S; Schumann A; Rau T; Glatz K; Behe M; Christ ER; Wild D
J Nucl Med; 2020 Apr; 61(4):520-526. PubMed ID: 31519804
[TBL] [Abstract][Full Text] [Related]
26. In Vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy.
Chan HS; de Blois E; Morgenstern A; Bruchertseifer F; de Jong M; Breeman W; Konijnenberg M
PLoS One; 2017; 12(7):e0181473. PubMed ID: 28732021
[TBL] [Abstract][Full Text] [Related]
27. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.
Delker A; Fendler WP; Kratochwil C; Brunegraf A; Gosewisch A; Gildehaus FJ; Tritschler S; Stief CG; Kopka K; Haberkorn U; Bartenstein P; Böning G
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):42-51. PubMed ID: 26318602
[TBL] [Abstract][Full Text] [Related]
28. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
[TBL] [Abstract][Full Text] [Related]
29. 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy.
Garkavij M; Nickel M; Sjögreen-Gleisner K; Ljungberg M; Ohlsson T; Wingårdh K; Strand SE; Tennvall J
Cancer; 2010 Feb; 116(4 Suppl):1084-92. PubMed ID: 20127957
[TBL] [Abstract][Full Text] [Related]
30. High-dose 166Ho-DOTMP in myeloablative treatment of multiple myeloma: pharmacokinetics, biodistribution, and absorbed dose estimation.
Rajendran JG; Eary JF; Bensinger W; Durack LD; Vernon C; Fritzberg A
J Nucl Med; 2002 Oct; 43(10):1383-90. PubMed ID: 12368378
[TBL] [Abstract][Full Text] [Related]
31. Biokinetics and Dosimetry of
Hänscheid H; Schirbel A; Hartrampf P; Kraus S; Werner RA; Einsele H; Wester HJ; Lassmann M; Kortüm M; Buck AK
J Nucl Med; 2022 May; 63(5):754-760. PubMed ID: 34413147
[TBL] [Abstract][Full Text] [Related]
32. 166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy.
Breitz HB; Wendt RE; Stabin MS; Shen S; Erwin WD; Rajendran JG; Eary JF; Durack L; Delpassand E; Martin W; Meredith RF
J Nucl Med; 2006 Mar; 47(3):534-42. PubMed ID: 16513624
[TBL] [Abstract][Full Text] [Related]
33. Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody.
D'Huyvetter M; Vincke C; Xavier C; Aerts A; Impens N; Baatout S; De Raeve H; Muyldermans S; Caveliers V; Devoogdt N; Lahoutte T
Theranostics; 2014; 4(7):708-20. PubMed ID: 24883121
[TBL] [Abstract][Full Text] [Related]
34. Intra-therapeutic dosimetry of [
Peters SMB; Privé BM; de Bakker M; de Lange F; Jentzen W; Eek A; Muselaers CHJ; Mehra N; Witjes JA; Gotthardt M; Nagarajah J; Konijnenberg MW
Eur J Nucl Med Mol Imaging; 2022 Jan; 49(2):460-469. PubMed ID: 34218300
[TBL] [Abstract][Full Text] [Related]
35. Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging.
Stillebroer AB; Zegers CM; Boerman OC; Oosterwijk E; Mulders PF; O'Donoghue JA; Visser EP; Oyen WJ
J Nucl Med; 2012 Jan; 53(1):82-9. PubMed ID: 22159179
[TBL] [Abstract][Full Text] [Related]
36. MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy.
Ljungberg M; Celler A; Konijnenberg MW; Eckerman KF; Dewaraja YK; Sjögreen-Gleisner K; ; Bolch WE; Brill AB; Fahey F; Fisher DR; Hobbs R; Howell RW; Meredith RF; Sgouros G; Zanzonico P; ; Bacher K; Chiesa C; Flux G; Lassmann M; Strigari L; Walrand S
J Nucl Med; 2016 Jan; 57(1):151-62. PubMed ID: 26471692
[TBL] [Abstract][Full Text] [Related]
37. Radiation safety of outpatient 177Lu-octreotate radiopeptide therapy of neuroendocrine tumors.
Calais PJ; Turner JH
Ann Nucl Med; 2014 Jul; 28(6):531-9. PubMed ID: 24687907
[TBL] [Abstract][Full Text] [Related]
38. Is there need for radioimmunotherapy? results of a phase I/II study in patients with indolent B-cell lymphomas using lutetium-177-DOTA-rituximab.
Forrer F; Oechslin-Oberholzer C; Campana B; Maecke H; Mueller-Brand J; Lohri A
Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):544-50. PubMed ID: 23358408
[TBL] [Abstract][Full Text] [Related]
39. Estimation of [177Lu]PSMA-617 tumor uptake based on voxel-wise 3D Monte Carlo tumor dosimetry in patients with metastasized castration resistant prostate cancer.
Götz TI; Lang EW; Prante O; Cordes M; Kuwert T; Ritt P; Ludwig B; Schmidkonz C
Nuklearmedizin; 2020 Sep; 59(5):365-374. PubMed ID: 32663888
[TBL] [Abstract][Full Text] [Related]
40. Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using
Baum RP; Schuchardt C; Singh A; Chantadisai M; Robiller FC; Zhang J; Mueller D; Eismant A; Almaguel F; Zboralski D; Osterkamp F; Hoehne A; Reineke U; Smerling C; Kulkarni HR
J Nucl Med; 2022 Mar; 63(3):415-423. PubMed ID: 34168013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
